Distal GI Lanthanum Dosage Form for Hyperoxaluria Without Phosphate Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperoxaluria, nephrolithiasis, and nephrocalcinosis, such as lanthanum carbonate and RNAi drugs, either cause phosphate depletion or are limited in efficacy and cost, lacking effective options for primary and secondary hyperoxaluria.
Innovation Solution
A pharmaceutical dosage form designed for targeted delivery to the distal gastrointestinal tract, specifically the ileum and colon, using lanthanum or its pharmaceutically acceptable salts or oxides, to chelate oxalate and reduce urinary oxalate concentration without causing phosphate depletion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lanthanum carbonate is used as an intestinal phosphate binder, then phosphate depletion occurs, but this leads to severe side effects such as osteomalacia and bone fractures
Solution Approach 1:
The patent applies local quality by targeting the distal gastrointestinal tract (ileum and colon) specifically for lanthanum release, rather than allowing systemic absorption. This localized action at the site of oxalate absorption enables phosphate binding without causing widespread phosphate depletion and its associated severe side effects like osteomalacia and bone fractures.
Solution Approach 2:
The patent uses an intermediary mechanism by employing a coating that releases lanthanum carbonate specifically in the distal GI tract. This intermediary delivery system allows the phosphate binder to function locally where it is needed (at the site of oxalate absorption) without interfering with systemic phosphate homeostasis.
2Reliability
If lanthanum carbonate is administered to decrease oxaluria, then calcium oxalate crystal formation is prevented, but phosphate depletion occurs
Solution Approach 1:
The patent resolves this contradiction by confining lanthanum action to the distal GI tract where oxalate absorption occurs. This localized phosphate binding at the site of oxalate exposure reduces oxalate absorption and prevents calcium oxalate crystal formation without causing systemic phosphate loss.
Solution Approach 2:
The patent segments the gastrointestinal tract into proximal and distal regions, applying different functional characteristics to each. The distal segment (ileum and colon) is specifically targeted for lanthanum release and oxalate binding, while the proximal segment maintains normal phosphate absorption, thus preventing phosphate depletion.
3Reliability
If RNAi drugs like lumasiran are used to treat primary hyperoxaluria, then glycolate oxidase is targeted, but the treatment cost is particularly high and response is not optimal
Solution Approach 1:
The patent employs a simple, cost-effective oral dosage form based on lanthanum carbonate with a targeted release coating. This straightforward formulation provides effective oxalate binding and hyperoxaluria treatment at a fraction of the cost of complex RNAi therapies like lumasiran, making the treatment more accessible.
Solution Approach 2:
The patent utilizes the body's own physiological processes (distal GI tract transit, local phosphate binding, oxalate chelation) to achieve therapeutic effects. This self-service mechanism eliminates the need for complex external delivery systems or expensive molecular biology-based therapies, providing a simple and cost-effective treatment approach.
4Reliability
If lanthanum is released in the proximal gastrointestinal tract, then phosphate binding occurs, but this interferes with phosphate absorption
Solution Approach 1:
The patent resolves this contradiction by applying different functional zones along the GI tract: the proximal region maintains normal phosphate absorption, while the distal region (ileum and colon) is specifically designed for lanthanum release and phosphate binding. This spatial differentiation allows phosphate binding without interfering with overall phosphate absorption.
Solution Approach 2:
The patent segments the GI tract functionally, assigning phosphate absorption to the proximal segment and phosphate binding/oxalate chelation to the distal segment. This segmentation allows both functions to operate simultaneously without interference, as each segment performs its specialized function in the appropriate location.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dosage form effectively decreases urinary oxalate and calcium concentrations, preventing calcium oxalate crystal formation, thereby reducing nephrolithiasis and maintaining phosphate balance, as demonstrated by substantial decreases in oxaluria and normal phosphate levels in patients.
Implementation Method 1
chelation of oxalate should start to get the combined effect of reduction of hyperoxaluria
Implementation Method 2
orally administrable pharmaceutical dosage form configured for targeted delivery to the distal part of the gastrointestinal tract
Data Source
AI summary
The invention concerns an orally administrable pharmaceutical dosage form configured for targeted delivery to the distal part of the gastrointestinal tract of a human subject, wherein the pharmaceutical dosage form comprises lanthanum or a pharmaceutically acceptable salt or oxide thereof. The invention further relates to the pharmaceutical dosage form for use in the treatment of hyperoxaluria in a human subject, optionally wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria; and/or for use in the treatment of one or more of nephrolithiasis, nephrocalcinosis, or oxalosis in a human subject.